Disclaimer: Information intended for healthcare professionals only. The production and printing of this Product Review supplement has been fully funded by Merck Sharp & Dohme Ltd.
Merck Sharp & Dohme Ltd suggested the topic and author, commented on the author brief, and provided the author’s honorarium. The content of the supplement has also been checked for factual accuracy, to ensure it is fair and balanced, and to ensure its compliance with appropriate regulations.
This supplement only displays the concise Technology Appraisal recommendations; readers are strongly advised to refer to the full Technology Appraisal guidance at www.nice.org.uk/ta385
The NICE guidance: Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia, Technology Appraisal 385 is reproduced with permission of NICE. NICE guidance is prepared for the National Health Service in England and Wales. All NICE guidance is subject to regular review and may be updated or withdrawn.
MGP Ltd owns copyright of the Guidelines brand, logo, and the design and format of this Guidelines supplement.